ImmuCell CorporationICCCNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank64
5Y CAGR+17.4%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+17.4%/yr
Long-term compound
Percentile
P64
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.32% |
| Q3 2025 | -16.53% |
| Q2 2025 | 9.91% |
| Q1 2025 | -7.63% |
| Q4 2024 | 4.23% |
| Q3 2024 | -23.71% |
| Q2 2024 | -18.38% |
| Q1 2024 | 18.44% |
| Q4 2023 | -4.69% |
| Q3 2023 | 1.72% |
| Q2 2023 | -0.98% |
| Q1 2023 | 5.81% |
| Q4 2022 | -17.35% |
| Q3 2022 | 11.50% |
| Q2 2022 | 9.93% |
| Q1 2022 | -4.95% |
| Q4 2021 | 4.04% |
| Q3 2021 | 4.74% |
| Q2 2021 | -3.00% |
| Q1 2021 | -11.87% |
| Q4 2020 | 4.17% |
| Q3 2020 | 3.36% |
| Q2 2020 | 11.51% |
| Q1 2020 | 0.20% |
| Q4 2019 | -1.25% |
| Q3 2019 | 20.09% |
| Q2 2019 | -9.93% |
| Q1 2019 | -27.92% |
| Q4 2018 | 38.98% |
| Q3 2018 | 19.28% |
| Q2 2018 | 30.70% |
| Q1 2018 | -20.58% |
| Q4 2017 | 25.29% |
| Q3 2017 | 51.38% |
| Q2 2017 | 13.95% |
| Q1 2017 | 33.85% |
| Q4 2016 | -17.54% |
| Q3 2016 | -19.11% |
| Q2 2016 | 25.79% |
| Q1 2016 | -8.67% |